ZA200709994B - Neurotherapeutic Azole Compounds - Google Patents
Neurotherapeutic Azole CompoundsInfo
- Publication number
- ZA200709994B ZA200709994B ZA200709994A ZA200709994A ZA200709994B ZA 200709994 B ZA200709994 B ZA 200709994B ZA 200709994 A ZA200709994 A ZA 200709994A ZA 200709994 A ZA200709994 A ZA 200709994A ZA 200709994 B ZA200709994 B ZA 200709994B
- Authority
- ZA
- South Africa
- Prior art keywords
- azole compounds
- neurotherapeutic
- neurotherapeutic azole
- compounds
- azole
- Prior art date
Links
- 150000003851 azoles Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67453005P | 2005-04-22 | 2005-04-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200709994B true ZA200709994B (en) | 2008-11-26 |
Family
ID=37115369
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200709994A ZA200709994B (en) | 2005-04-22 | 2007-11-20 | Neurotherapeutic Azole Compounds |
Country Status (21)
Country | Link |
---|---|
US (1) | US7598279B2 (xx) |
EP (1) | EP1879873B1 (xx) |
JP (1) | JP5035238B2 (xx) |
KR (1) | KR101286499B1 (xx) |
CN (1) | CN101228138B (xx) |
AR (1) | AR053065A1 (xx) |
AU (1) | AU2006237798B2 (xx) |
BR (1) | BRPI0607529B8 (xx) |
CA (1) | CA2606258C (xx) |
DK (1) | DK1879873T3 (xx) |
ES (1) | ES2441765T3 (xx) |
FI (1) | FIC20210018I1 (xx) |
MX (1) | MX2007013197A (xx) |
MY (1) | MY148589A (xx) |
NL (1) | NL301106I2 (xx) |
PL (1) | PL1879873T3 (xx) |
PT (1) | PT1879873E (xx) |
RU (1) | RU2418792C2 (xx) |
TW (1) | TWI398249B (xx) |
WO (1) | WO2006112685A1 (xx) |
ZA (1) | ZA200709994B (xx) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7598279B2 (en) | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
PT2155736E (pt) * | 2007-05-14 | 2012-03-28 | Sk Biopharmaceuticals Co Ltd | Novo composto carbamoiloxiarilalcanoilarilpiperazina, composições farmacêuticas compreendendo este composto e método para tratamento da dor, ansiedade e depressão pela administração do composto |
US8188301B2 (en) | 2007-06-05 | 2012-05-29 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission |
JP5527668B2 (ja) * | 2008-06-05 | 2014-06-18 | エスケー バイオファーマスティカルズ カンパニー リミテッド | 3−置換プロパンアミン化合物 |
WO2010150946A1 (en) * | 2009-06-22 | 2010-12-29 | Sk Holdings Co., Ltd. | Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester |
US8404461B2 (en) * | 2009-10-15 | 2013-03-26 | SK Biopharmaceutical Co. Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
RU2557533C2 (ru) | 2009-11-06 | 2015-07-20 | Ск Биофармасъютиклс Ко., Лтд. | Способы лечения синдрома фибромиалгии |
AU2010316106B2 (en) | 2009-11-06 | 2015-10-22 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating attention-deficit/hyperactivity disorder |
US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
CA2860577C (en) * | 2012-01-06 | 2020-09-15 | Spinifex Pharmaceuticals Pty Ltd | Heterocyclic compounds as angiotensin ii type 2 receptor antagonists |
US9630896B2 (en) | 2013-11-22 | 2017-04-25 | Tansna Therapeutics, Inc. | 2,5-dialkyl-4-H/halo/ether-phenol compounds |
TWI655179B (zh) * | 2014-02-28 | 2019-04-01 | 南韓商愛思開生物製藥股份有限公司 | 胺基羰基胺基甲酸酯化合物 |
ITUA20161941A1 (it) * | 2016-03-23 | 2017-09-23 | Univ Degli Studi Di Siena | Uso di derivati dell’acido 2-amminotiofen-3- carbossilico per il trattamento delle dipendenze da cibo |
KR102489052B1 (ko) * | 2016-05-19 | 2023-01-16 | 에스케이바이오팜 주식회사 | 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 |
KR102421006B1 (ko) * | 2016-05-19 | 2022-07-14 | 에스케이바이오팜 주식회사 | 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도 |
KR102421013B1 (ko) * | 2016-05-19 | 2022-07-14 | 에스케이바이오팜 주식회사 | 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 |
AU2017374458B2 (en) * | 2016-12-14 | 2023-03-02 | Sk Biopharmaceuticals Co., Ltd. | Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder |
ES2975254T3 (es) * | 2016-12-14 | 2024-07-04 | Sk Biopharmaceuticals Co Ltd | Uso de compuestos de carbamato para la prevención, alivio o tratamiento del prurito |
EP3556365A4 (en) * | 2016-12-14 | 2020-06-17 | SK Biopharmaceuticals Co., Ltd. | USE OF A CARBAMATE COMPOUND FOR THE PREVENTION, RELIEF OR TREATMENT OF A DEMYLINATING DISEASE |
AU2017374450B2 (en) * | 2016-12-14 | 2023-05-11 | Sk Biopharmaceuticals Co., Ltd. | Parenteral liquid preparation comprising carbamate compound |
EP3556345B1 (en) * | 2016-12-14 | 2021-09-22 | SK Biopharmaceuticals Co., Ltd. | Orally disintegrated tablet comprising carbamate compound |
US11033531B2 (en) * | 2016-12-14 | 2021-06-15 | Sk Biopharmaceuticals Co., Ltd. | Use of carbamate compound for preventing, alleviating, or treating tremors or tremor syndrome |
BR112020009310A2 (pt) * | 2017-11-14 | 2020-10-13 | Sk Biopharmaceuticals Co., Ltd. | combinação e composição farmacêutica para a prevenção, alívio ou tratamento da esquizofrenia. |
WO2019098633A1 (ko) * | 2017-11-14 | 2019-05-23 | 에스케이바이오팜 주식회사 | 내장통 또는 내장 질환에서 기인한 통증을 예방, 경감 또는 치료하기 위한 카바메이트 화합물의 용도 |
US11389429B2 (en) | 2017-11-14 | 2022-07-19 | Sk Biopharmaceuticals Co., Ltd. | Use of carbamate compound for preventing, alleviating or treating myotonia |
CA3081223A1 (en) * | 2017-11-14 | 2019-05-23 | Sk Biopharmaceuticals Co., Ltd. | Use of carbamate compound for preventing, alleviating or treating absence seizure or epilepsy showing absence seizure |
KR102739580B1 (ko) * | 2017-11-14 | 2024-12-06 | 에스케이바이오팜 주식회사 | 후기 나트륨 전류의 증가와 관련된 질환을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 |
CN111432814B (zh) * | 2017-11-14 | 2024-05-14 | 爱思开生物制药株式会社 | 用于减轻或治疗包括脆性X染色体综合征、Angelman综合征或Rett综合征的发育障碍的氨基甲酸酯化合物的用途 |
ES2978226T3 (es) * | 2018-09-21 | 2024-09-09 | Sk Biopharmaceuticals Co Ltd | Compuesto de carbamato y uso de la formulación que lo comprende para prevenir, aliviar o tratar el trastorno de estrés agudo o el trastorno de estrés postraumático |
JP7417595B2 (ja) * | 2018-09-21 | 2024-01-18 | エスケー バイオファーマスティカルズ カンパニー リミテッド | てんかん重積状態の予防、軽減又は治療のためのカルバメート化合物の使用 |
TWI826531B (zh) * | 2018-09-21 | 2023-12-21 | 南韓商愛思開生物製藥股份有限公司 | 具有㗁二唑之化合物及包含該化合物之醫藥組合物 |
JP7369185B2 (ja) * | 2018-10-19 | 2023-10-25 | エスケー バイオファーマスティカルズ カンパニー リミテッド | カルバメート化合物の糖尿病性末梢神経障害又は化学療法剤誘発性末梢神経障害の予防、緩和又は治療のための使用 |
US10611737B1 (en) | 2019-10-24 | 2020-04-07 | Sk Biopharmaceuticals Co., Ltd. | Method for preparing aryl 2-tetrazol-2-yl ketone with improved selectivity |
EP4062906A4 (en) * | 2019-11-22 | 2024-01-03 | SK Biopharmaceuticals Co., Ltd. | ORAL PHARMACEUTICAL COMPOSITION COMPRISING A CARBAMATE COMPOUND AND METHOD FOR PREPARING THIS COMPOSITION |
US20230338295A1 (en) * | 2020-08-06 | 2023-10-26 | Sk Biopharmaceuticals Co., Ltd. | Solid oral composition comprising carbamate compound, and preparation method therefor |
CN114317620B (zh) * | 2020-09-29 | 2024-02-02 | 上海医药工业研究院 | 一种(r)-2-(2-氯苯基)环氧乙烷的生物制备方法 |
AR125970A1 (es) | 2021-05-28 | 2023-08-30 | Sk Biopharmaceuticals Co Ltd | Formulaciones de suspensión acuosa para administración oral que comprenden un compuesto de carbamato |
CN115974799B (zh) * | 2021-10-14 | 2024-08-13 | 成都百裕制药股份有限公司 | 氨基甲酸酯取代的醇衍生物及其在医药上的应用 |
ES2931000B2 (es) * | 2022-07-14 | 2023-07-07 | Univ Madrid Complutense | Proceso para la preparación de cenobamato |
CN115716810A (zh) * | 2022-11-15 | 2023-02-28 | 江苏艾立康医药科技有限公司 | 一种西诺氨酯的晶体形式及其制备方法 |
CN118239901A (zh) * | 2023-03-15 | 2024-06-25 | 江苏恩华药业股份有限公司 | 一种氨基甲酸(r)-1-(2-氯苯基)-2-四唑-2-基乙酯的晶体 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3415840A (en) | 1965-10-22 | 1968-12-10 | American Home Prod | Pyrazole-1-ethanol derivatives |
DK181988A (da) | 1988-03-30 | 1989-10-01 | Dumex Ltd As | Thiocarbamidsyreester til brug som terapeutikum samt praeparat til behandling af alkoholmisbrug |
BR0210678A (pt) * | 2001-06-25 | 2004-09-21 | Sk Corp | Carbamatos de 2-heterocìclicos-1,2-etanodióis |
US6770659B2 (en) * | 2002-08-26 | 2004-08-03 | Sk Corporation | Benzoyl piperidine compounds |
US7598279B2 (en) | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
-
2006
- 2006-04-20 US US11/407,526 patent/US7598279B2/en active Active
- 2006-04-21 KR KR1020077026985A patent/KR101286499B1/ko active Active
- 2006-04-21 CA CA2606258A patent/CA2606258C/en active Active
- 2006-04-21 RU RU2007143073/04A patent/RU2418792C2/ru active
- 2006-04-21 JP JP2008507557A patent/JP5035238B2/ja active Active
- 2006-04-21 AU AU2006237798A patent/AU2006237798B2/en active Active
- 2006-04-21 EP EP06768472.0A patent/EP1879873B1/en active Active
- 2006-04-21 CN CN2006800134724A patent/CN101228138B/zh active Active
- 2006-04-21 BR BRPI0607529A patent/BRPI0607529B8/pt active IP Right Grant
- 2006-04-21 AR ARP060101598A patent/AR053065A1/es active IP Right Grant
- 2006-04-21 MX MX2007013197A patent/MX2007013197A/es active IP Right Grant
- 2006-04-21 PT PT67684720T patent/PT1879873E/pt unknown
- 2006-04-21 ES ES06768472.0T patent/ES2441765T3/es active Active
- 2006-04-21 WO PCT/KR2006/001523 patent/WO2006112685A1/en active Application Filing
- 2006-04-21 PL PL06768472T patent/PL1879873T3/pl unknown
- 2006-04-21 TW TW095114655A patent/TWI398249B/zh active
- 2006-04-21 DK DK06768472.0T patent/DK1879873T3/da active
- 2006-04-24 MY MYPI20061865A patent/MY148589A/en unknown
-
2007
- 2007-11-20 ZA ZA200709994A patent/ZA200709994B/xx unknown
-
2021
- 2021-05-31 NL NL301106C patent/NL301106I2/nl unknown
- 2021-06-14 FI FIC20210018C patent/FIC20210018I1/fi unknown
Also Published As
Publication number | Publication date |
---|---|
NL301106I1 (nl) | 2021-06-02 |
MX2007013197A (es) | 2008-02-12 |
CN101228138A (zh) | 2008-07-23 |
AR053065A1 (es) | 2007-04-18 |
KR20080005437A (ko) | 2008-01-11 |
AU2006237798B2 (en) | 2012-07-12 |
JP5035238B2 (ja) | 2012-09-26 |
BRPI0607529B8 (pt) | 2021-05-25 |
EP1879873A1 (en) | 2008-01-23 |
JP2008538557A (ja) | 2008-10-30 |
RU2007143073A (ru) | 2009-05-27 |
CA2606258A1 (en) | 2006-10-26 |
DK1879873T3 (da) | 2013-12-09 |
PT1879873E (pt) | 2014-01-03 |
TWI398249B (zh) | 2013-06-11 |
BRPI0607529A2 (pt) | 2009-09-15 |
US7598279B2 (en) | 2009-10-06 |
KR101286499B1 (ko) | 2013-07-16 |
AU2006237798A1 (en) | 2006-10-26 |
PL1879873T3 (pl) | 2014-03-31 |
ES2441765T3 (es) | 2014-02-06 |
NL301106I2 (nl) | 2021-08-03 |
EP1879873A4 (en) | 2011-06-15 |
CA2606258C (en) | 2014-01-14 |
WO2006112685A1 (en) | 2006-10-26 |
MY148589A (en) | 2013-05-15 |
TW200722085A (en) | 2007-06-16 |
US20060258718A1 (en) | 2006-11-16 |
EP1879873B1 (en) | 2013-10-09 |
FIC20210018I1 (fi) | 2021-06-14 |
BRPI0607529B1 (pt) | 2021-05-18 |
CN101228138B (zh) | 2012-11-21 |
RU2418792C2 (ru) | 2011-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200709994B (en) | Neurotherapeutic Azole Compounds | |
IL190450A0 (en) | Substituted pyrazole compounds | |
EP1847531A4 (en) | PYRAZOLE DERIVATIVE | |
GB0503962D0 (en) | Compounds | |
SI1870409T1 (sl) | Spojine benzimidazola | |
GB0502418D0 (en) | Compounds | |
GB0502316D0 (en) | Compounds | |
AP2007004220A0 (en) | Motilide compounds | |
EP1907385A4 (en) | LINKS | |
GB0502310D0 (en) | Compounds | |
GB0502299D0 (en) | Compounds | |
GB0503961D0 (en) | Compounds | |
GB0505084D0 (en) | Compounds | |
ZA200802786B (en) | Substituted pyrazole compounds | |
GB0505086D0 (en) | Compounds | |
EP1867650A4 (en) | HYDROXYMETHYLBORVERBINDUNGEN | |
GB0501985D0 (en) | Compounds | |
GB0501984D0 (en) | Compounds | |
GB0505085D0 (en) | Compounds | |
GB0519486D0 (en) | Compounds | |
GB0503145D0 (en) | Compounds | |
GB0501838D0 (en) | Compounds | |
GB0503846D0 (en) | Compounds | |
GB0500889D0 (en) | Compounds | |
GB0500891D0 (en) | Compounds |